**July 2026** --- July's cervical cancer literature centered on how much work remains to make sure prevention reaches everyone. Vaccination remained the biggest engine of progress this month: new real-world effectiveness data from China, promising modeling for a therapeutic HPV vaccine, and a sobering look at rising vaccine hesitancy among young women all appeared alongside a wave of screening innovations built around self-collected HPV samples. Global equity ran through nearly everything published this month, from access gaps in wealthy countries like Australia to structural barriers in Ghana, Ethiopia, and Eswatini, and several papers focused specifically on women living with HIV, who continue to carry a disproportionate share of the world's cervical cancer burden. Treatment research for locally advanced and recurrent disease also continued to move forward, including new data on chemotherapy combinations and targeted antibody-based treatments for people whose cancer has spread or returned. Overall, July reinforced that cervical cancer, more than almost any other cancer, is a story about closing gaps - in vaccination, in screening access, and in who gets to benefit from what science already knows how to do. *The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist.* This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused. --- **HPV vaccination keeps proving itself, but hesitancy is a real and growing headwind** Cervical cancer is one of the very few cancers with a vaccine that can prevent it in the first place, and this month's research kept building the case for how well that vaccine works in the real world, while also flagging a genuine warning sign about public trust. - The strongest evidence came from a large umbrella review pulling together ecological and real-world studies: HPV vaccination showed up to 99% efficacy against persistent infection with HPV types 16 and 18 (the two types responsible for the majority of cervical cancers), and vaccinated populations saw 57-88% reductions in cervical cancer and precancerous changes. This is about as strong a confirmation as public health research gets that the vaccine is doing exactly what it was designed to do ([Read the full paper](https://doi.org/10.1080/21645515.2026.2699584)). - A matched real-world study of over 7,000 vaccinated and unvaccinated women aged 18-45 in China found vaccine effectiveness reached 40.2% at two or more years after vaccination, which is lower than the near-total protection seen in adolescents vaccinated before any HPV exposure, a reminder that vaccinating earlier, before sexual debut, offers the strongest protection ([Read the full paper](https://doi.org/10.1080/21645515.2026.2693440)). - Looking beyond prevention, Chinese researchers modeled the potential impact of a therapeutic HPV vaccine (a vaccine designed to help the immune system clear an existing HPV infection, rather than prevent one) and estimated it could avert up to 834,000 cervical cancer cases and move up national elimination timelines by roughly 11 years if it reaches the market and is deployed at scale. This is still a modeling exercise, not a proven therapy, but it points to where prevention research may be headed next ([Read the full paper](https://doi.org/10.1186/s12916-026-05050-0)). - Not all the vaccine news was reassuring. Two national surveys of Chinese female university students found HPV vaccine hesitancy nearly tripled, from 8.8% in 2022 to 21.6% in 2025, even as HPV knowledge improved. The researchers linked this to eroding public trust rather than lack of information, a pattern worth watching anywhere vaccine confidence is being tested ([Read the full paper](https://doi.org/10.1080/21645515.2026.2701549)). - A scoping review of 46 studies across the World Health Organization's South-East Asia Region found HPV vaccine coverage remains uneven across countries and proposed a more integrated implementation model to help the region catch up. It’s a useful reminder that "the vaccine works" and "everyone can access the vaccine" are two very different statements ([Read the full paper](https://doi.org/10.1080/21645515.2026.2693359)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Screening keeps getting easier to access and self-collection is becoming the norm, not the exception** For decades, cervical cancer screening meant a clinician-performed exam. This month's research confirmed that self-collected HPV samples, where a person collects their own vaginal swab, often at home or in a private setting, are now standard enough to study at scale, and that screening technology keeps getting smarter about who needs closer follow-up. - A global narrative review traced how cervical screening has evolved from Pap smear cytology to HPV DNA testing to self-sampling, framing self-collection as the next major access breakthrough rather than a niche option ([Read the full paper](https://doi.org/10.2147/IJWH.S607741)). - In Australia, researchers surveyed healthcare providers about self-collection for people with physical disabilities and found it was seen as highly acceptable but rarely offered in practice, meaning there is a gap between what's possible and what's actually happening in clinics ([Read the full paper](https://doi.org/10.1186/s12889-026-28364-3)). - A Norwegian study of women with mildly abnormal Pap results (called ASC-US or LSIL — borderline or low-grade cell changes that need follow-up to rule out anything more serious) found that testing for specific HPV genotypes at the RNA level could safely cut immediate colposcopy referrals by 59.2%, meaning fewer people would need an invasive follow-up procedure they don't actually need ([Read the full paper](https://doi.org/10.3390/pathogens15070747)). - A large study of more than 75,000 women in Indonesian metropolitan areas found HPV infection peaked between ages 30 and 39 and dropped sharply after 65, supporting a recommended screening age range of 25 to 65. This is useful real-world data for shaping national screening guidelines ([Read the full paper](https://doi.org/10.31557/APJCP.2026.27.7.2541)). - Simulation research using real HPV testing data from Bangladesh and Uganda found that pooling multiple samples into a single test, a cost-saving lab technique, could cut the number of tests needed by 15-77%, potentially stretching limited screening budgets much further in lower-income countries ([Read the full paper](https://doi.org/10.7189/jogh.16.04275)). - Perhaps the most reassuring finding of the month: fifty years of German cancer registry data showed cervical cancer incidence has fallen 74% since Pap screening began in 1971, alongside a more than tenfold rise in detection of in-situ carcinoma (cancer cells found only in the surface layer, before they've invaded deeper tissue), providing concrete, long-term proof that consistent screening saves lives ([Read the full paper](https://doi.org/10.1002/cam4.72127)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Closing the global equity gap** Cervical cancer is disproportionately a disease of low- and middle-income countries, and it also leaves specific communities everywhere underserved. This month's research repeatedly returned to the practical, on-the-ground barriers that stand between people and care that already exists. - A systematic review of 32 studies from Ghana identified layered barriers to screening, from individual fear and stigma to weak health system capacity, that interact with each other, meaning no single fix (like just adding more clinics) will close the gap on its own ([Read the full paper](https://doi.org/10.1136/bmjopen-2025-111770)). - A qualitative study in Ethiopia described how fear, stigma, supply failures, and inconsistent funding compound across individual, community, and policy levels, arguing that scaling up screening requires coordinated action at all of these levels simultaneously, not just more awareness campaigns ([Read the full paper](https://doi.org/10.1016/j.eclinm.2026.104057)). - Even in wealthy countries, access isn't guaranteed: an Australian "secret shopper" study, where researchers posed as new patients calling general practices, found 23% of practices couldn't offer a cervical screening appointment at all, with real regional variation in whether self-collection was even offered ([Read the full paper](https://doi.org/10.1007/s10552-026-02215-3)). - A U.S. study found that sexual and gender minority women had meaningfully lower cervical cancer screening rates than their peers, part of a broader pattern of disparities across colorectal, cervical, and breast cancer screening, providing evidence that care teams need to actively invite LGBTQ+ patients into routine screening rather than assuming it will happen on its own ([Read the full paper](https://doi.org/10.1002/cncr.70462)). - In Botswana, researchers checking vaccination records for adolescent girls living with HIV found only 18.8% had verifiable documentation of their HPV vaccine doses, not necessarily because girls weren't vaccinated, but because record-keeping systems weren't capturing it, which matters because incomplete records can lead to missed booster doses or unnecessary re-vaccination ([Read the full paper](https://doi.org/10.3389/fpubh.2026.1821335)). - Focus groups with young Korean women identified stigma tied to sexual activity as a major barrier to both screening and vaccination. People avoided care because seeking it felt like an admission about their sexual history, a dynamic that shows up in cervical cancer prevention research across many cultures ([Read the full paper](https://doi.org/10.1371/journal.pone.0353242)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Cervical cancer and immune health: HIV and beyond** People living with HIV, and people with autoimmune conditions on immune-suppressing treatment, face substantially higher risk of HPV-related disease, and this month's research put real numbers behind why this community needs more attention, not less. - A multi-country study following HIV-positive women in resource-limited settings after thermal ablation (a heat-based treatment for precancerous cervical lesions) found 12-month HPV persistence of 40% and a 4% recurrence rate of higher-grade precancer, both strongly tied to whether HPV16 (a particularly high-risk HPV type) was still detectable at follow-up. That's a concrete signal for care teams about who needs closer monitoring after treatment ([Read the full paper](https://doi.org/10.1002/ijc.70648)). - In South Africa, researchers found cervical cancer mortality among women rose 12% between 2014 and 2018 despite high antiretroviral therapy (ART) coverage, and proposed an integrated model combining existing HIV care infrastructure with HPV self-sampling to close the gap ([Read the full paper](https://doi.org/10.2147/IJWH.S613391)). - A nationally representative survey in Eswatini found only 48.2% of women aged 25–59 had ever been screened for cervical cancer, with HIV-positive status actually associated with higher odds of screening, likely reflecting that women already engaged in HIV care have more contact with the health system ([Read the full paper](https://doi.org/10.1371/journal.pone.0354508)). - Two modeling and program studies focused on the same intersection from different angles: mathematical models estimated that catch-up HPV vaccination for South African women living with HIV could avert up to 14% of their cervical cancer cases over the next 55-60 years, while a 12-month program in Nigeria that sensitized mothers and adolescent daughters together, including HIV-affected families, significantly increased HPV awareness, vaccination uptake, and maternal screening ([Read the full paper](https://doi.org/10.1002/jia2.70149), [Read the full paper](https://doi.org/10.1002/jia2.70164)). - It's not only HIV that raises risk. Two French studies of patients with immune-mediated inflammatory diseases (autoimmune conditions like lupus or inflammatory bowel disease, often treated with immune-suppressing medication) found that 20% of patients overdue for screening tested positive for high-risk HPV, and that patients, especially women with lupus, had nearly double the risk of HPV-induced cancer or severe dysplasia compared to matched peers without these conditions. If you're being treated for an autoimmune condition, this is a good reason to make sure your cervical screening stays current, even if it feels like one more appointment to keep track of ([Read the full paper](https://doi.org/10.1136/rmdopen-2026-006955), [Read the full paper](https://doi.org/10.1136/rmdopen-2026-006927)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Managing precancerous change: what the latest evidence shows** Most cervical cancer starts as a slow, gradual progression through precancerous cell changes, often called CIN (cervical intraepithelial neoplasia), graded 1 to 3 by severity, and catching and managing this stage well is one of the most effective ways to prevent cancer from developing at all. - A large Danish study following over 10,500 women found no difference in adverse pregnancy outcomes between active surveillance (monitoring CIN2 without immediate treatment) and immediate excision, which is reassuring news for women of reproductive age who are weighing whether treating a precancerous change now might affect a future pregnancy ([Read the full paper](https://doi.org/10.1111/aogs.70304)). - A meta-analysis of 19 studies and over 3,300 patients found that photodynamic therapy using 5-aminolevulinic acid (a light-activated topical treatment, often called ALA-PDT) achieved higher response rates and HPV clearance than simple observation or ablation for cervical squamous intraepithelial lesions, performing comparably to conization (surgical removal of a cone-shaped piece of cervical tissue) while avoiding an invasive procedure ([Read the full paper](https://doi.org/10.1007/s10103-026-04955-9)). - A separate study of 240 patients with CIN I (the mildest grade of precancerous change) found that a specific ALA-PDT protocol (five hours of topical application followed by 40 minutes of light exposure) achieved the highest cure rates and lowest recurrence, correlating with clearance of HPV16 and HPV18 ([Read the full paper](https://doi.org/10.3389/fonc.2026.1889112)). - An international panel of experts published a consensus statement suggesting that an adjuvant vaginal gel may help HPV-positive women with low-grade cervical lesions clear the virus and see lesions regress faster, particularly for women over 40 ([Read the full paper](https://doi.org/10.3390/medicina62071283)). - Not all news was reassuring: a systematic review of colposcopy-based "see-and-treat" approaches (where a suspicious-looking lesion is treated in the same visit as diagnosis, without waiting for a biopsy result) found substantial inconsistency in the visual criteria doctors use, with overtreatment rates as high as 72.5% for CIN3. This serves as a reminder to ask your care team how confident they are before agreeing to treat in the same visit as your colposcopy ([Read the full paper](https://doi.org/10.1016/j.ejogrb.2026.115330)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Surgery and fertility preservation** For people diagnosed at an early stage who hope to preserve their fertility, this month brought incremental but meaningful progress on both surgical technique and how doctors decide who's a good candidate for less invasive approaches. - A comparative cohort study found robotic radical hysterectomy resulted in less blood loss, shorter hospital stays, and a higher lymph node yield than open surgery for early-stage cervical cancer, with tumor size - not which surgical approach was used - predicting whether the pathology looked more aggressive afterward ([Read the full paper](https://doi.org/10.3390/jcm15135168)). - Radiologists proposed a structured MRI protocol for assessing how deeply a tumor has grown into the cervical stroma (the supportive tissue of the cervix), which has become a key factor in deciding who's eligible for less radical, fertility-sparing surgery since the SHAPE and ConCerv trials. A more standardized, checklist-based approach to this imaging could help more patients get consistent, accurate answers about their surgical options ([Read the full paper](https://doi.org/10.1007/s00261-026-05693-w)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Immunotherapy and targeted therapy in recurrent and metastatic disease** For people whose cervical cancer has returned or spread, immune checkpoint inhibitors and antibody-drug conjugates (a targeted treatment that pairs a cancer-seeking antibody with a chemotherapy payload, delivering the drug directly to tumor cells while sparing healthy tissue) have become central to care over the past several years, and research into how to use them well continues month by month. *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Precision medicine, rare subtypes, and treatment innovation** Alongside incremental clinical advances, this month's research included early but promising work on understanding cervical cancer at the molecular level, recognizing rarer high-risk subtypes, and using imaging to guide treatment more precisely. - Researchers characterized a newly defined, aggressive cervical cancer subtype called "poorly cohesive carcinoma" in 16 patients, predominantly linked to HPV type 18, with a 50% mortality rate and mutations in the KRAS and KMT2C genes. This provodes early evidence that this needs to be recognized as its own high-risk category rather than lumped in with more common cervical cancer types ([Read the full paper](https://doi.org/10.1002/2056-4538.70100)). - In laboratory research using a new HPV-negative cervical cancer model, genomic profiling identified deficiencies in the BRCA2, RAD51, and MLH1 genes (all involved in repairing DNA damage) that made the cancer cells especially sensitive to a PARP inhibitor (olaparib, a drug that blocks a backup DNA-repair pathway cancer cells rely on), especially when combined with platinum chemotherapy. This is preclinical work, not yet tested in patients, but it points toward a possible precision-medicine strategy for a cervical cancer subtype that doesn't respond to standard HPV-targeted approaches ([Read the full paper](https://doi.org/10.1038/s41598-026-59964-z)). - A Japanese study of 281 patients found that how much a tumor shrinks on MRI partway through radiation treatment independently predicted overall survival, progression-free survival, and local control, suggesting that mid-treatment imaging could help identify, early on, who might benefit from a more intensive approach ([Read the full paper](https://doi.org/10.1093/jrr/rrag043)). - In India, a quality-improvement project using a bundled clinical workflow raised the share of patients completing radiotherapy within the recommended 56-day window from 18.6% to 70.1%, serving as a reminder that treatment delays aren't just about access to equipment, but also about how care is organized and tracked ([Read the full paper](https://doi.org/10.1136/bmjoq-2025-003874)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Survivorship and life after treatment** Finishing treatment is not the end of the story, and this month's research kept the focus on what comes after - physically, hormonally, and in terms of access to ongoing care. - A study of 132 cervical cancer survivors found that radiotherapy caused the most pronounced long-term urinary dysfunction and decline in quality of life and sexual function. There was only a weak relationship between what doctors measured objectively and what patients actually reported feeling, meaning there is a good reason to bring up symptoms even if a clinical test doesn't show an obvious problem ([Read the full paper](https://doi.org/10.3389/fonc.2026.1853725)). - A position paper from FIGO (the International Federation of Gynecology and Obstetrics) concluded that systemic menopausal hormone therapy may be appropriate for carefully selected survivors of gynecologic cancers that aren't hormone-driven, which includes most cervical cancers, while hormonally sensitive tumors should still avoid it. If treatment pushed you into early menopause, this is worth raising directly with your oncologist or gynecologist ([Read the full paper](https://doi.org/10.1002/ijgo.71188)). - A pilot program in Rwanda tested moving cervical cancer survivorship follow-up care out of centralized cancer centers and into district hospitals closer to where patients live, meeting feasibility, safety, and acceptability benchmarks while cutting patients' travel time and cost by roughly 75%. This is a promising model for making follow-up care realistic for people who don't live near a major hospital ([Read the full paper](https://doi.org/10.1093/oncolo/oyag275)). *Check the citations section for a comprehensive list of publications associated with this topic.* --- **General and basic-science cervical cancer research** Alongside the findings above, a steady stream of laboratory and bioinformatics research this month continued to build the foundation for tomorrow's treatments: identifying genes and pathways involved in cervical cancer growth and chemotherapy resistance, and exploring biomarkers that may one day guide care. None of this is ready for the clinic yet, but it's the pipeline that later-stage research draws from. *Check the citations section for a comprehensive list of publications associated with this topic.* --- **What Does This Mean for Me?** **If you're newly diagnosed and considering fertility preservation:** This month's research on MRI-based assessment of stromal invasion depth and robotic surgical outcomes both point toward more precise, individualized decisions about whether less radical, fertility-sparing surgery is right for you. Ask your surgical team directly: based on my imaging and tumor characteristics, am I a candidate for a fertility-sparing approach, and what would that surgery involve? It's also reasonable to ask whether your cancer center uses the newer imaging protocols described this month, since not every hospital has adopted them yet. **If you have a precancerous diagnosis (CIN1, CIN2, or CIN3):** You have more legitimate options than "treat immediately" versus "do nothing." This month's research supports active surveillance as a reasonable choice for CIN2 if you're pregnant or planning pregnancy soon, and photodynamic therapy as an effective, less invasive alternative to surgical excision for some patients. Ask your care team: given my specific grade of change and my life circumstances, what are all of my options, not just the default one? And if you're offered same-visit "see-and-treat," it's fair to ask how confident your provider is in that visual assessment, given how often it leads to treating things that would have resolved on their own. **If your cancer has recurred or spread:** Immune checkpoint inhibitors and antibody-drug conjugates remain the most active area of treatment development for recurrent and metastatic cervical cancer, and this month's citations include current research on how these treatments are being combined and refined. Ask your oncology team what your options look like today, since this is a fast-moving area of treatment, and whether a clinical trial testing a newer combination might be appropriate for your situation. **If you're a survivor dealing with lingering side effects:** Urinary, sexual, and menopausal symptoms after treatment are common, real, and worth bringing up even if a test result looks normal. This month's research specifically found that patient-reported symptoms and objective clinical measurements often don't match up well. If treatment brought on early menopause, ask specifically about menopausal hormone therapy; new guidance this month suggests it may be a reasonable option for many cervical cancer survivors, which wasn't always the assumption in the past. **If you're at risk or thinking about prevention for yourself or a family member:** The vaccine remains the single most effective tool available, and it works best given before any HPV exposure. If you have an adolescent in your life who hasn't been vaccinated yet, this is a good year to raise it with their doctor. If you're overdue for screening yourself, ask whether self-collection is available where you get care; it's increasingly common and, this month's research suggests, works just as well as a clinician-collected sample for most people. Whatever situation you're in, know that clinical trials are one way to access emerging treatments and contribute to the research that shapes care for the next person diagnosed. Ask your oncology team whether any trials might be a fit for you, and know that OCRA (Ovarian Cancer Research Alliance) offers resources and support for people navigating a gynecologic cancer diagnosis, even outside of ovarian cancer specifically. You don't have to sort through research like this alone. Visit [ocrahope.org](http://ocrahope.org) to learn about OCRA's resources and how to connect with the broader gynecologic cancer community. *This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.* --- **Sources** *Citations are grouped by the topic sections above. Within each section, the papers directly referenced in the digest are listed first, followed by additional on-topic papers published this month that are either not discussed above or are behind access restrictions.* **HPV vaccination keeps proving itself, but hesitancy is a real and growing headwind** ***Directly referenced:*** 1. Rahim F, Atasever Ü. "Population impact of HPV vaccination on cancer/pre-cancer outcomes, umbrella review." *Hum Vaccin Immunother.* July 6, 2026. PMID 42409728. 2. Luo B, et al. "Real-world HPV vaccine effectiveness in women aged 18-45, China." *Hum Vaccin Immunother.* July 10, 2026. PMID 42429434. 3. Pan C, et al. "Potential health impact of therapeutic HPV vaccines in China, modeling." *BMC Med.* July 7, 2026. PMID 42415033. 4. Zhang, et al. "Changes in HPV vaccine hesitancy and influencing factors among female university students in China: A national repeated study." *Human Vaccines & Immunotherapeutics.* July 29, 2026. PMID 42525964. 5. Kolambkar, et al. "HPV vaccination in the WHO South-East Asia Region: A scoping review of uptake, implementation challenges, and pathways to acceleration." *Human Vaccines & Immunotherapeutics.* July 28, 2026. PMID 42518306. ***Additional citations on related topics:*** 6. Hermann KC, et al. "HPV vaccine perceptions/access among parents and providers, Quito Ecuador." *Glob Public Health.* July 3, 2026. PMID 42396795. *(41 interviews: low awareness HPV causes cancer in men, fear of side effects.)* 7. Al-Omair, et al. "Health-related social media engagement and cervical cancer prevention: HPV knowledge, vaccine awareness, and pap smear utilization among US women." *Frontiers in Public Health.* July 7, 2026. PMID 42483066. *(Health-related social media engagement was associated with significantly higher HPV knowledge, vaccine awareness, and Pap smear utilization among US women.)* 8. Wang, et al. "Factors influencing HPV vaccination intention and uptake among medical students based on health belief model and vaccine hesitancy theory." *Frontiers in Public Health.* July 9, 2026. PMID 42494906. *(Among Chinese medical students, HPV knowledge was linked to vaccination intention/behavior.)* 9. Ghilencea, et al. "Natural Versus Vaccine-Induced Immunity Against HPV: A Comparative Review of Antibody Response and Cancer Prevention." *Antibodies (Basel).* July 13, 2026. PMID 42496287. *(HPV vaccine-induced immunity produces durable antibody responses superior to natural infection.)* 10. Li, et al. "Policy events, emotional fluctuations, and vaccination behavior: a longitudinal analysis of public opinion on HPV vaccines in China." *Frontiers in Public Health.* July 14, 2026. PMID 42491271. *(An analysis of social media sentiment found HPV vaccine opinion in China shifted with policy changes and past safety incidents.)* 11. Abdulghani N, et al. "Educational intervention improving parents' HPV vaccine knowledge, Saudi Arabia." *BMC Public Health.* July 3, 2026. PMID 42393589. *(restricted license, CC BY-NC-ND 4.0)* 12. Gyamfi-Samakome, et al. "Impact of health education intervention on knowledge and attitude towards HPV vaccination in Africa: A systematic review." *Vaccine.* July 17, 2026. PMID 42468223. *(subscription access)* 13. Hellner K, et al. "Phase 1b/2 RCT VTP-200 therapeutic HPV vaccine, low-grade cervical lesions." *Clin Infect Dis.* July 23, 2026. PMID 41403292. *(subscription access)* **Screening keeps getting easier to access and self-collection is becoming the norm, not the exception** ***Directly referenced:*** 14. Rakhat A, Aimagambetova G. "Cervical Cancer Screening in Transition: global challenges review." *Int J Womens Health.* July 2, 2026. PMID 42441303. 15. Flynn K, et al. "Self-collection to improve cervical screening access for people with physical disability, Australia." *BMC Public Health.* July 10, 2026. PMID 42432590. 16. Sørbye, et al. "Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL (Tromsø Cohort)." *Pathogens.* July 17, 2026. PMID 42515074. 17. Utami, et al. "Unveiling Optimal Cervical Cancer Screening Age Range: HPV Infection Among 75,719 Women in Indonesia's Metropolitan Regions." *Asian Pac J Cancer Prev.* July 26, 2026. PMID 42522815. 18. Pan, et al. "Efficient high-risk human papillomavirus screening through pooled testing: a simulation study in LMICs." *Journal of Global Health.* July 24, 2026. PMID 42495948. 19. Rath, et al. "Analysis of Age, Period and Cohort Trends in Cervical In Situ and Invasive Carcinomas — Saarland Cancer Registry." *Cancer Medicine.* July 2026. PMID 42482636. ***Additional citations on related topics:*** 20. Ozdas, et al. "Women's experiences and perspectives on a nurse navigation program for cervical cancer screening: a qualitative study." *Frontiers in Public Health.* July 1, 2026. PMID 42459472. *(A nurse navigation program was found to improve women's engagement, knowledge, and comfort with cervical cancer screening.)* 21. Weatherhead, et al. "Enhancing efficiency and improving turnaround time: real-world impact of the Genius Digital Diagnostics System implementation." *Am J Clinical Pathology.* July 6, 2026. PMID 42480093. *(Real-world implementation of AI-assisted digital cytology boosted lab efficiency without hurting diagnostic accuracy.)* 22. Berza N, et al. "Factors in women's choice of cervical sampling mode, Latvia." *PLoS One.* July 9, 2026. PMID 42424363. *(A survey of 1,217 women found a roughly even split between preference for clinician-collected and self-collected screening.)* 23. Bülbü, et al. "Self-collected versus clinician-collected human papillomavirus samples." *Rev Assoc Med Bras.* July 20, 2026. PMID 42484181. *(Self-collected HPV samples performed comparably to clinician-collected samples with high patient satisfaction.)* 24. Wilson, et al. "Improving laboratory workforce efficiency using AI-assisted digital cytology within an HPV-based cervical screening programme (NHS)." *BMJ Open.* July 28, 2026. PMID 42526933. *(A modeling study estimated AI-assisted cytology could substantially cut lab staff review time in the UK's national screening program.)* 25. Arroyo Mühr LS, et al. "Global HPV typing/screening proficiency panels 2008-2024." *J Med Virol.* July 2026. PMID 42370736. *(WHO's HPV laboratory proficiency testing network grew from 54 to more than 130 participating labs.)* 26. Yang Y, et al. "Fluorescence-colorimetric cysteine detection in urine for cervical cancer screening." *Anal Methods.* July 2, 2026. PMID 42300479. *(subscription access)* 27. Pourette D, et al. "Motivation/capacity/opportunity for home HPV self-sampling, Réunion Island." *BMC Public Health.* July 11, 2026. PMID 42432545. *(restricted license, CC BY-NC-ND 4.0)* 28. Hansen, et al. "Women's experiences, responses, and coping strategies when testing positive for HPV in cervical cancer screening." *Acta Obstet Gynecol Scand.* July 27, 2026. PMID 42504858. *(restricted license, CC BY-NC-ND 4.0)* 29. Ng, et al. "Effect of Self-Sampling HPV DNA Testing on Cervical Cancer Screening in Singapore's Primary Care: Pragmatic RCT." *Annals of Family Medicine.* July 27, 2026. PMID 42509175. *(access restricted, license unconfirmed)* **Closing the global equity gap** ***Directly referenced:*** 30. Lanyo GS, et al. "Determinants of cervical screening in Ghana, systematic review." *BMJ Open.* July 9, 2026. PMID 42425573. 31. Lahole, et al. "Challenges of scaling up cervical cancer screening in Ethiopia: a qualitative socio-ecological study." *EClinicalMedicine.* July 9, 2026. PMID 42473536. 32. Boyd, et al. "Access to cervical screening in Australian general practices: a cross-sectional study using a 'secret shopper' approach." *Cancer Causes & Control.* July 22, 2026. PMID 42484709. 33. Arena L, et al. "SOGI disparities in colorectal/cervical/breast cancer screening." *Cancer.* July 15, 2026. PMID 42403041. 34. Jammalamadugu, et al. "Individual-level HPV vaccination verification in Botswana: lessons learned from implementation of the HOPE II trial." *Frontiers in Public Health.* July 1, 2026. PMID 42459477. 35. Kim HJ, et al. "Barriers/facilitators to cervical cancer prevention, young Korean women." *PLoS One.* July 10, 2026. PMID 42430333. ***Additional citations on related topics:*** 36. Kaur, et al. "Awareness of and Barriers to Cervical Cancer Screening among Married Tribal Women in Sirohi, Rajasthan." *Asian Pac J Cancer Prev.* July 1, 2026. PMID 42522806. *(A community study of tribal women in Rajasthan found critically low knowledge and poor screening practices.)* 37. Ramaliba TM, et al. "Incidence trends of 4 cancers, rural South Africa." *Cancer Epidemiol.* July 2, 2026. PMID 42391785. *(Cervical cancer made up 36.4% of the cancers studied, with incidence rising 3.8% per year.)* 38. Zenebe, et al. "Perceived facilitators and barriers against human papillomavirus vaccine among rural parents with eligible daughters, Southern Ethiopia." *PLoS One.* July 22, 2026. PMID 42485289. *(Trust in health professionals was a key facilitator of HPV vaccine acceptance among rural Ethiopian parents.)* 39. Silva, et al. "Cervical cancer screening in incarcerated women: deprived of freedom or deprived of health?." *Rev Bras Enferm.* July 24, 2026. PMID 42524965. *(A reflective review calling for stronger nursing-led cervical screening in prisons.)* 40. Kase, et al. "Changing burden of cancers related to human papillomavirus in Estonia: a population-based registry study." *Acta Oncologica.* July 27, 2026. PMID 42504768. *(Estonian registry data show cervical cancer incidence declining even as other HPV-related cancers rise.)* 41. Sheppard AJ, et al. "Screening program cancer outcomes in First Nations people, Ontario." *JAMA Netw Open.* July 1, 2026. PMID 42430169. *(restricted license, CC BY-NC-ND)* 42. Swisher, et al. "Cervical Cancer Screening With Human Papillomavirus Self-Collection Testing in an Opioid Treatment Program." *JAMA Network Open.* July 1, 2026. PMID 42525415. *(restricted license, CC BY-NC-ND 4.0)* 43. Hassan UM, et al. "Readiness and affordability of HPV testing in Gombe, Nigeria." *Int J Gynaecol Obstet.* July 2, 2026. PMID 42388037. *(subscription access)* 44. Kessler LG, et al. "Validity of survey questions on cancer screening (4 cancers)." *Am J Epidemiol.* July 8, 2026. PMID 41755645. *(access restricted, license unconfirmed)* 45. McArdle, et al. "Triangular Partnership in Oncology: The Kenya-Nepal Oncology Network Project for the Control of Breast and Cervical Cancer." *JCO Global Oncology.* July 17, 2026. PMID 42467882. *(restricted license, CC BY-NC-ND)* **Cervical cancer and immune health: HIV and beyond** ***Directly referenced:*** 46. Debeaudrap, et al. "Follow-Up and Outcomes After Thermal Ablation Treatment Among HIV-Infected Women From Resource-Limited Countries With Positive HPV-Based Screening (AIMA-CC)." *Int J Cancer.* July 15, 2026. PMID 42458722. 47. Adefolalu. "Cervical Cancer Screening in Women Living with HIV in South Africa: Addressing Health Disparities." *Int J Women's Health.* July 21, 2026. PMID 42516296. 48. Tafese, et al. "Cervical cancer screening coverage and associated factors among women aged 25-59 in Eswatini (2021 PHIA)." *PLoS One.* July 22, 2026. PMID 42485322. 49. Doyle, et al. "Potential Impact of Catch-Up HPV Vaccination on HPV Prevalence and Cervical Cancer Incidence Among Women Living With HIV in South Africa." *J Int AIDS Society.* July 2026. PMID 42499184. 50. Peter, et al. "From Awareness to Action: Improving HPV Knowledge, Screening and Vaccine Uptake Among Mother-Adolescent Pairs (HOMINY Study, Nigeria)." *J Int AIDS Society.* July 2026. PMID 42499163. 51. Goulenok, et al. "Prevalence and risk factors for high-risk human papillomavirus infection in patients with immune-mediated inflammatory diseases." *RMD Open.* July 15, 2026. PMID 42457210. 52. Gros, et al. "Risk of cancer induced by human papillomavirus in patients with immune-mediated inflammatory diseases: a nationwide matched cohort study." *RMD Open.* July 15, 2026. PMID 42457219. ***Additional citations on related topics:*** 53. Bergman, et al. "HIV and Human Papilloma Virus Community Service Integration Among Women: A Systematic Review and Narrative Synthesis." *J Assoc Nurses AIDS Care.* July 16, 2026. PMID 42460889. *(subscription access)* **Managing precancerous change: what the latest evidence shows** ***Directly referenced:*** 54. Katholm KK, et al. "Active surveillance of CIN2 and adverse pregnancy outcomes, Denmark." *Acta Obstet Gynecol Scand.* July 1, 2026. PMID 42383805. 55. Guo, et al. "Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for cervical squamous intraepithelial lesion: a systematic review and meta-analysis." *Lasers in Medical Science.* July 18, 2026. PMID 42470528. 56. Yu, et al. "Evaluation of efficacy and optimal therapeutic parameters of ALA-PDT in HPV-associated CIN I." *Frontiers in Oncology.* July 10, 2026. PMID 42500281. 57. Cortés, et al. "Multidisciplinary Expert Consensus on Management of HPV-Positive Women with Low-Grade Cervical Lesions and Vaginal Treatment." *Medicina (Kaunas).* July 3, 2026. PMID 42512825. 58. Damen, et al. "Macroscopic prediction of cervical dysplasia at colposcopy for see-and-treat patient selection: a systematic review." *Eur J Obstet Gynecol Reprod Biol.* July 19, 2026. PMID 42492476. ***Additional citations on related topics:*** 59. Ybaseta-Medina J, et al. "Cervical ectropion associated with high-grade cervical dysplasia." *BMC Womens Health.* July 3, 2026. PMID 42399914. *(Peruvian case-control: ectropion significantly more common in dysplasia cases.)* 60. Zouzoulas D, et al. "MODUCIN1 trial protocol: Moducare vs wait-and-see for CIN1." *PLoS One.* July 13, 2026. PMID 42441577. *(Protocol for a planned Greek trial testing a dietary supplement versus standard monitoring for CIN1.)* 61. Geng L, et al. "ALA-photodynamic therapy plus CO2 laser for CIN2." *Sci Rep.* July 1, 2026. PMID 42386837. *(restricted license, CC BY-NC-ND 4.0)* 62. Mohammadian S, et al. "CO2 laser ablation vs conization for CIN2." *Lasers Med Sci.* July 11, 2026. PMID 42432338. *(restricted license, CC BY-NC-ND 4.0)* **Surgery and fertility preservation** ***Directly referenced:*** 63. Jędrzejczyk, et al. "Robotic Versus Open Radical Hysterectomy in Early-Stage Cervical Cancer: A Comparative Cohort Study." *Journal of Clinical Medicine.* July 2, 2026. PMID 42452628. 64. Murad, et al. "Shaping surgical decisions: a practical MRI approach to cervical stromal invasion assessment in the post-SHAPE era." *Abdominal Radiology.* July 24, 2026. PMID 42496917. **Immunotherapy and targeted therapy in recurrent and metastatic disease** ***Additional citations on related topics:*** 65. Farolfi, et al. "Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer." *JAMA Network Open.* July 1, 2026. PMID 42446878. *(restricted license, CC BY-NC-ND)* 66. Sridhar, et al. "Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity." *Clinical Cancer Research.* July 17, 2026. PMID 42467245. *(restricted license, CC BY-NC-ND)* **Precision medicine, rare subtypes, and treatment innovation** ***Directly referenced:*** 67. Liu W, et al. "HPV-associated cervical poorly cohesive carcinoma characterization." *J Pathol Clin Res.* July 2026. PMID 42289532. 68. Polten, et al. "Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model." *Scientific Reports.* July 29, 2026. PMID 42527451. 69. Saito T, et al. "Mid-treatment MRI tumor volume reduction as prognostic factor." *J Radiat Res.* July 24, 2026. PMID 42348783. 70. Bonala SR, et al. "Quality improvement for radiotherapy compliance in cervical cancer, India." *BMJ Open Qual.* July 6, 2026. PMID 42409422. ***Additional citations on related topics:*** 71. Pei, et al. "Nomogram for Preoperative Prediction of Adjuvant Therapy Requirement Following Radical Surgery in Stage IB Cervical Squamous Cell Carcinoma With Tumor Size ≤4cm." *Cancer Medicine.* July 2026. PMID 42449501. *(A nomogram using preoperative lab and pathological factors predicted need for adjuvant therapy after radical surgery for stage IB cervical SCC.)* 72. Netherton TJ, et al. "AI radiotherapy planning tool for cervical and prostate cancer." *JCO Glob Oncol.* July 9, 2026. PMID 42424567. *(A dual-cancer AI tool produced clinically acceptable radiotherapy plans in most test cases.)* 73. Menon, et al. "A prospective development and evaluation of a 2D convolutional neural network-based auto-segmentation model for cervical cancer radiotherapy." *J Egyptian Natl Cancer Inst.* July 15, 2026. PMID 42455232. *(An AI model cut radiotherapy contouring time from 77 minutes to 5 seconds per case.)* 74. Suzuki T, et al. "Patient stratification for brachytherapy dose scaling." *J Radiat Res.* July 24, 2026. PMID 42411646. *(A small study found tumor histology could help identify who benefits most from higher radiation doses.)* 75. Boku, et al. "Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events." *Gan To Kagaku Ryoho.* July 2026. PMID 42551928. (no DOI available) *(access restricted, license unconfirmed)* 76. Ismayilov R, Altundag O. "RE: Tertiary lymphoid structure/prognosis, gastric-type endocervical adenocarcinoma." *J Natl Cancer Inst.* July 1, 2026. PMID 41975243. *(subscription access)* 77. Dayani D, et al. "Neuroendocrine Carcinoma of Cervix: comprehensive review." *Semin Ultrasound CT MR.* July 3, 2026. PMID 42398637. *(subscription access)* 78. Casarin, et al. "Surgical volume, structural quality, and compliance with ESGO quality indicators in endometrial and cervical cancer." *Int J Gynecol Cancer.* July 3, 2026. PMID 42501475. *(subscription access)* 79. Jian J, et al. "Transformer MR-to-CT synthesis for cervical cancer radiotherapy." *Biomed Phys Eng Express.* July 6, 2026. PMID 42341776. *(restricted license, CC BY-NC-ND 4.0)* 80. Tian, et al. "Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review)." *Int J Molecular Medicine.* July 17, 2026. PMID 42464673. *(restricted license, CC BY-NC-ND 4.0)* 81. Zhu, et al. "Interpretable machine learning models for preoperative precision prediction of perineural invasion in cervical cancer." *J Southern Medical University.* July 20, 2026. PMID 42486820. *(subscription access)* 82. Kang OJ, et al. "Gastric-type histology predicts poor survival in cervical adenocarcinoma." *Anticancer Res.* July 2026. PMID 42373253. *(subscription access)* **Survivorship and life after treatment** ***Directly referenced:*** 83. Bereza, et al. "Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment." *Frontiers in Oncology.* July 2, 2026. PMID 42465566. 84. da Silva-Filho, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: FIGO position paper." *Int J Gynaecol Obstet.* July 22, 2026. PMID 42483786. 85. Rubagumya, et al. "Feasibility of decentralized cervical cancer survivorship care at district hospitals in Rwanda: a multi-site pilot implementation study." *The Oncologist.* July 8, 2026. PMID 42464010. ***Additional citations on related topics:*** 86. Xu, et al. "Efficacy of Transcutaneous Electrical Acupoint Stimulation as an Adjunct to Bladder Training After Radical Hysterectomy for Cervical Cancer: RCT." *Current Oncology.* July 16, 2026. PMID 42505226. *(A randomized trial found this add-on therapy improved some but not all bladder recovery measures.)* 87. Bereza, et al. "Correction: Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment." *Frontiers in Oncology.* July 20, 2026. PMID 42549158. *(A correction notice for the urinary dysfunction/quality-of-life study above; no new findings.)* 88. Lee, et al. "Validity of HINT-8 in evaluating health-related quality of life among cervical cancer patients." *J Comparative Effectiveness Research.* July 24, 2026. PMID 42496163. *(restricted license, CC BY-NC-ND 4.0)* 89. Gonçalves, et al. "Second primary cancers among females with a first primary cervical, uterine and ovarian cancer: North Portugal." *Cancer Causes & Control.* July 28, 2026. PMID 42518015. *(subscription access)* 90. Currier, et al. "Female allogeneic hematopoietic cell transplant survivors' perspectives on cervical cancer screening." *Supportive Care in Cancer.* July 30, 2026. PMID 42527718. *(subscription access)* **General and basic-science cervical cancer research** ***Additional citations on related topics:*** 91. Pan, et al. "Mitochondrial reprogramming in cervical cancer: crosstalk with tumor immunity, HPV oncogenic signaling, and therapeutic resistance." *Frontiers in Immunology.* July 8, 2026. PMID 42488672. *(A review of how HPV-driven changes to tumor metabolism may shape immune evasion and treatment resistance.)* 92. Sayer, et al. "Cisplatin and ε-Viniferin Synergistically Modulate Oxidative Stress in HeLa Cells." *Molecules.* July 8, 2026. PMID 42513092. *(Preclinical lab study combining chemotherapy with a plant compound to increase cancer cell death.)* 93. Chen ML, et al. "MiR-4327 targets TP53 to promote cervical cancer proliferation." *Funct Integr Genomics.* July 11, 2026. PMID 42432185. *(Preclinical research on a microRNA pathway that promotes cervical cancer cell growth.)* 94. Mishra, et al. "Longitudinal analysis of high-risk HPV infections reveals within-host viral genome changes over time." *PLoS Pathogens.* July 15, 2026. PMID 42455819. *(Laboratory research on how the HPV virus changes within the body during progression to precancer or cancer.)* 95. Huang, et al. "Spatially organized macrophage-T-cell crosstalk in cervical cancer: insights from single-cell and spatial omics." *Frontiers in Immunology.* July 15, 2026. PMID 42529136. *(A review of how immune cells organize within cervical tumors, proposing future immunotherapy strategies.)* 96. Chen, et al. "Cross-scale modeling reveals a TFRC-driven immunosuppressive macrophage niche in cervical cancer." *Frontiers in Immunology.* July 17, 2026. PMID 42539625. *(Laboratory research identifying a gene signature linked to immune suppression within cervical tumors.)* 97. Santos, et al. "Cell-Free DNA Fragmentation Patterns as Biomarkers for Human Papillomavirus-Related Cancers: Systematic Review." *Int J Molecular Sciences.* July 17, 2026. PMID 42511713. *(A meta-analysis exploring whether circulating cell-free DNA patterns could help diagnose HPV-driven cancers, including cervical cancer.)* 98. Luo, et al. "A prognostic signature based on methionine metabolism-related genes for cervical cancer." *PeerJ.* July 21, 2026. PMID 42500207. *(A gene-based model to help predict cervical cancer patient risk and candidate drug response.)* 99. Huang, et al. "RNA-Binding Protein RBMS3 Inhibits Cervical Cancer Progression by Enhancing HSPA6 mRNA Stability." *Frontiers in Bioscience (Landmark Ed).* July 24, 2026. PMID 42530257. *(Laboratory research identifying a protein that suppresses cervical cancer growth.)* 100. Long, et al. "SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression." *PLoS One.* July 27, 2026. PMID 42507688. *(Laboratory research on a gene pathway linked to chemotherapy resistance.)* 101. Abadia ACM, et al. "Cytotoxic effect of Dysphania ambrosioides extracts on breast/cervical cancer cells." *Chem Biodivers.* July 2026. PMID 42424091. *(Preclinical lab study of a plant extract's effects on breast and cervical cancer cell lines.)* 102. Cheng, et al. "Global trends and insights in cervical cancer research: a bibliometric analysis from 2000 to 2024." *Reproduction & Fertility.* July 1, 2026. PMID 42446903. *(restricted license, CC BY-NC-ND 4.0)* 103. Zhang Y, et al. "WFDC2 promotes cervical cancer via ERK/NF-kB signaling." *Oncol Rep.* July 3, 2026. PMID 42396650. *(subscription access)* 104. Lin X, et al. "Shared genetic features between cervical cancer and venous thromboembolism." *Comput Biol Chem.* July 8, 2026. PMID 42424909. *(subscription access)* 105. Chen X, et al. "Malignant keratinization state linked to immune exclusion in cervical squamous carcinoma." *J Transl Med.* July 9, 2026. PMID 42426811. *(restricted license, CC BY-NC-ND 4.0)* 106. Ganga VS, et al. "Esculin targeting PARP1 in cervical cancer, in silico." *Comput Biol Chem.* July 10, 2026. PMID 42430944. *(subscription access)* 107. Ghosh, et al. "Long non-coding RNAs: a new hope for the cervical cancer staging." *Molecular Biology Reports.* July 18, 2026. PMID 42470499. *(subscription access)* 108. Chen, et al. "Integrative multi-omics analysis identifies FAM3D as a prognostic tumor suppressor in cervical cancer." *Functional & Integrative Genomics.* July 21, 2026. PMID 42479091. *(restricted license, CC BY-NC-ND 4.0)* 109. Chen, et al. "Mucus and tumor penetrating paclitaxel micelles for potent local therapy of cervical cancer." *J Nanobiotechnology.* July 22, 2026. PMID 42522017. *(restricted license, CC BY-NC-ND 4.0)* 110. Dong X, et al. "CdTe quantum dot biosensor for APE1 activity in cervical cancer cell lysates." *Anal Methods.* July 23, 2026. PMID 42338417. *(subscription access)* 111. Li, et al. "Siglec-15 Enhances Cisplatin Resistance in Cervical Cancer Cells by Promoting Mitochondrial Retrograde Signaling Through Activation of the MAPK Pathway." *DNA and Cell Biology.* July 23, 2026. PMID 42494126. *(subscription access)* 112. Makise, et al. "Stable overexpression of Nup88 enhances HeLa cell migration through independent regulation of Kif7 and Gli1." *Oncology Reports.* July 24, 2026. PMID 42495774. *(restricted license, CC BY-NC-ND 4.0)* 113. Zheng, et al. "LncRNA DNM3OS suppresses proliferation, invasion, and epithelial-mesenchymal transition in cervical cancer cells via miR-454-3p." *Molecular Biology Reports.* July 29, 2026. PMID 42525155. *(subscription access)* 114. Ahn, et al. "Anticancer effects of tangeretin associated with reactive oxygen species generation, mitochondrial dysfunction and apoptosis in CaSki cells." *Oncology Reports.* July 31, 2026. PMID 42535404. *(restricted license, CC BY-NC-ND 4.0)* --- *A note on how this digest was made: This edition was built by searching PubMed for papers published in July 2026, using a two-tier strategy — targeted thematic searches across the cervical cancer landscape (treatment, immunotherapy, ADCs, HPV vaccination, screening, disparities, surgery, molecular subtypes, precancer, survivorship, rare subtypes) plus a dedicated qualitative search and a broad MeSH sweep. Papers summarized in full are open-access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.*

This Month in Cervical Cancer Research

Published